Unraveling the Potential of Empagliflozin to Counteract 1,2-Dimethylhydrazine-Induced Colorectal Cancer in Rats: Involvement of Redox Imbalance, Inflammatory Cascades, and Unprogrammed Cell Proliferation.

Globally, colorectal cancer ranks second in terms of mortality and is the third most frequent cancer. This study was designed to evaluate empagliflozin ability to suppress the progression of 1,2-dimethylhydrazine (DMH)-induced colorectal cancer. An 8-week regimen of 40 mg/kg/twice a week of DMH to generate colorectal cancer. Three groups of eight male Wistar rats were created as follows: normal control, DMH group and DMH + empagliflozin (30 mg/kg; p.o.). The colonic levels of the antioxidant enzymes; superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) were restored, empagliflozin adjusted the redox imbalance provoked by DMH. Immunohistochemical study proved the impact of empagliflozin in downregulating nuclear factor kappa B (NF-κB) that was elevated by DMH. Empagliflozin counteracted the DMH-triggered inflammation by reducing vascular endothelial growth factor (VEGF), interlukin-6 (IL-6) and cyclooxygenase-2 (COX-2) levels. Empagliflozin hindered tumor cell proliferation which has supported by the decline in proliferating cell nuclear antigen (PCNA) mRNA expression. Empagliflozin halted the DMH-activated oncogenic phosphatidylinositol 3 kinase (PI3K)/protein kinase B (Akt)/the mammalian target of rapamycin (mTOR) signaling pathway, demonstrated by western blot analysis. Histopathological assessment verified that empagliflozin suppressed the formation of dysplastic aberrant crypt foci (ACF). Empagliflozin has been suggested to suppress the progression of colorectal carcinogenesis.